AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15118618 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 microg ethinyl estradiol + 150 microg desogestrel followed by 2 days of placebo then 10 microg ethinyl estradiol for 5 days
Number of subjects: 54
Study 15118618 — intervention group
Group type: EXPERIMENTAL
Intervention: 28 days of 20 microg ethinyl estradiol + 150 microg desogestrel
Number of subjects: 54
Study 15118618 — intervention group
Group type: COMPARATOR
Intervention: 7-day pill-free interval
Number of subjects: 54
Study 15118618 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight women (BMI > 25 kg/m²)
Number of subjects: 54
Study 11310514 — intervention group
Group type: EXPERIMENTAL
Intervention: Rx medibottle
Number of subjects: 30
Study 11310514 — intervention group
Group type: COMPARATOR
Intervention: Oral syringe
Number of subjects: 30
Study 9141918 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial administration of epinephrine at 100 ng.kg‐1.min‐1
Number of subjects: 10
Study 9141918 — intervention group
Group type: COMPARATOR
Intervention: Right atrial administration of epinephrine at 100 ng.kg‐1.min‐1
Number of subjects: 10
Study 7894222 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 230
Study 7894222 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 230
Study 7894222 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) and Unfractionated heparin
Number of subjects: 230
Study 3690032 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg almitrine
Number of subjects: 58
Study 3690032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 31462757 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT)
Number of subjects: 20
Study 29376761 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 8.75 mg spray
Number of subjects: 505
Study 29376761 — intervention group
Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 505
Study 26928760 — intervention group
Group type: EXPERIMENTAL
Intervention: Before CPB
Number of subjects: 101
Study 26928760 — intervention group
Group type: EXPERIMENTAL
Intervention: After CPB
Number of subjects: 101
Study 25911115 — intervention group
Group type: EXPERIMENTAL
Intervention: Culprit lesions with plaque rupture
Number of subjects: 80
Study 25911115 — intervention group
Group type: EXPERIMENTAL
Intervention: Culprit lesions without plaque rupture
Number of subjects: 80
Study 25911115 — intervention group
Group type: EXPERIMENTAL
Intervention: Culprit lesions with calcified nodules
Number of subjects: 80
Study 25911115 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT at 6 months for lesions with plaque rupture
Number of subjects: 80
Study 25911115 — intervention group
Group type: COMPARATOR
Intervention: OCT at 6 months for lesions without plaque rupture
Number of subjects: 80
Study 22981306 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS-RUTFh (soy/maize/sorghum ready-to-use therapeutic food)
Number of subjects: 41
Study 22981306 — intervention group
Group type: COMPARATOR
Intervention: Control (P-RUTF; peanut-butter/milk-powder paste)
Number of subjects: 41
Study 22981306 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS-RUTFh
Number of subjects: 41
Study 20536334 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity stress group (n = 13)
Number of subjects: 27
Study 20536334 — intervention group
Group type: COMPARATOR
Intervention: No-stress control group (n = 14)
Number of subjects: 27
Study 18720323 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body hypothermia (N = 4)
Number of subjects: 9
Study 18720323 — intervention group
Group type: COMPARATOR
Intervention: Usual care (N = 5)
Number of subjects: 9
Study 16796150 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish-oil (4 g/day)
Number of subjects: 400
Study 16796150 — intervention group
Group type: COMPARATOR
Intervention: Soy-oil (4 g/day)
Number of subjects: 400
Study 12605201 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous 12-lead ECG monitoring
Number of subjects: 119
Study 12605201 — intervention group
Group type: COMPARATOR
Intervention: Chest pain unit protocol
Number of subjects: 119
Study 12605201 — intervention group
Group type: EXPERIMENTAL
Intervention: ST-segment changes (greater than 100 microV in 2 or more contiguous leads or greater than 200 microV in 1 lead)
Number of subjects: 119
Study 10799796 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative pain medications before educational program
Number of subjects: 0
Study 10799796 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative pain medications after educational program
Number of subjects: 0
Study 10799796 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of acute postoperative pain medication
Number of subjects: 0
Study 8638023 — intervention group
Group type: EXPERIMENTAL
Intervention: EP-guided antiarrhythmic drug therapy (propafenone, flecainide, disopyramide, sotalol, amiodarone)
Number of subjects: 398
Study 8638023 — intervention group
Group type: EXPERIMENTAL
Intervention: Empiric amiodarone
Number of subjects: 398
Study 8638023 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (in patients with implantable cardioverter/defibrillator)
Number of subjects: 398
Study 8638023 — intervention group
Group type: COMPARATOR
Intervention: Empiric metoprolol
Number of subjects: 398
Study 1597023 — intervention group
Group type: EXPERIMENTAL
Intervention: E5 2.5 mg/kg
Number of subjects: 39
Study 1597023 — intervention group
Group type: EXPERIMENTAL
Intervention: E5 7.5 mg/kg
Number of subjects: 39
Study 1597023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 1597023 — intervention group
Group type: EXPERIMENTAL
Intervention: E5
Number of subjects: 39
Study 3904810 — intervention group
Group type: EXPERIMENTAL
Intervention: Etretinate
Number of subjects: 0
Study 3904810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30314856 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTI-BREAK intervention (3×5min active breaks incorporated into classroom routine daily)
Number of subjects: 374
Study 30314856 — intervention group
Group type: COMPARATOR
Intervention: Usual teaching practice (control group)
Number of subjects: 374
Study 29305792 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal bupivacaine hydrochloride (30 cm3, 0.25%)
Number of subjects: 120
Study 29305792 — intervention group
Group type: COMPARATOR
Intervention: Control group (no bupivacaine hydrochloride)
Number of subjects: 120
Study 27208511 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive Outreach (AO) program
Number of subjects: 295
Study 27208511 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 295
Study 24697278 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release cilostazol formulation
Number of subjects: 0
Study 24697278 — intervention group
Group type: COMPARATOR
Intervention: Pletal (twice-daily immediate-release formulation)
Number of subjects: 0
Study 22543813 — intervention group
Group type: EXPERIMENTAL
Intervention: Active experimental group (30-min exercise session)
Number of subjects: 4
Study 22543813 — intervention group
Group type: COMPARATOR
Intervention: Active control group (monitored physical activity)
Number of subjects: 4
Study 22543813 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-active experimental group (30-min exercise session)
Number of subjects: 4
Study 22543813 — intervention group
Group type: COMPARATOR
Intervention: Non-active control group (monitored physical activity)
Number of subjects: 4
Study 20400005 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 1.3 mg/kg
Number of subjects: 88
Study 20400005 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 1.6 mg/kg
Number of subjects: 88
Study 20400005 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2.0 mg/kg
Number of subjects: 88
Study 20400005 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2.3 mg/kg
Number of subjects: 88
Study 17122976 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 192
Study 17122976 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 192
Study 17122976 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 192
Study 16377698 — intervention group
Group type: EXPERIMENTAL
Intervention: BAL8557 (100 mg of BAL4815)
Number of subjects: 48
Study 16377698 — intervention group
Group type: EXPERIMENTAL
Intervention: BAL8557 (200 mg of BAL4815)
Number of subjects: 48
Study 16377698 — intervention group
Group type: EXPERIMENTAL
Intervention: BAL8557 (400 mg of BAL4815)
Number of subjects: 48
Study 16377698 — intervention group
Group type: EXPERIMENTAL
Intervention: BAL8557 (50 mg of BAL4815)
Number of subjects: 48
Study 14645770 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse prevention intervention
Number of subjects: 386
Study 14645770 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 386
Study 10808172 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg with loratadine 10 mg
Number of subjects: 460
Study 10808172 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg
Number of subjects: 460
Study 10808172 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 460
Study 10808172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 460
Study 8673937 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac oral 10 mg at six hour intervals for 24 hours
Number of subjects: 3
Study 8673937 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac injectable 10 mg at the height/depth of the buccal vestibule of the tooth to be treated
Number of subjects: 3
Study 8673937 — intervention group
Group type: COMPARATOR
Intervention: No assigned medication (control group)
Number of subjects: 3
Study 1633067 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide 60 mg as two oral controlled release (CR) formulations
Number of subjects: 26
Study 1633067 — intervention group
Group type: COMPARATOR
Intervention: Plain tablets of Frusemide 60 mg
Number of subjects: 26
Study 6094278 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole alone for 4 months (group A)
Number of subjects: 30
Study 6094278 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole in combination with chemical nail avulsion (group B)
Number of subjects: 30
Study 6094278 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 30
Study 31250992 — intervention group
Group type: EXPERIMENTAL
Intervention: RPh201 (5 mg, 10 mg, 20 mg) in SAD stage
Number of subjects: 39
Study 31250992 — intervention group
Group type: EXPERIMENTAL
Intervention: RPh201 (5 mg, 10 mg, 20 mg) in MAD stage
Number of subjects: 39
Study 31250992 — intervention group
Group type: COMPARATOR
Intervention: Placebo in SAD stage
Number of subjects: 39
Study 31271330 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncemented joint replacement (Elektra)
Number of subjects: 40
Study 31271330 — intervention group
Group type: COMPARATOR
Intervention: Trapeziectomy (with ligament reconstruction and tendon interposition, LRTI)
Number of subjects: 40
Study 31271330 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint replacement (Elektra)
Number of subjects: 40
Study 28923692 — intervention group
Group type: EXPERIMENTAL
Intervention: BioFreedom DCS
Number of subjects: 72
Study 26487907 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord blood 25-hydroxyvitamin D concentration
Number of subjects: 270
Study 23508198 — intervention group
Group type: EXPERIMENTAL
Intervention: Instruction aimed at improving knee abduction during jump landings
Number of subjects: 26
Study 23508198 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based training following initial instruction
Number of subjects: 26
Study 23508198 — intervention group
Group type: COMPARATOR
Intervention: Sham training (Control)
Number of subjects: 26
Study 21821621 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of clinical items indicative of inflammatory back pain for diagnosing axial spondyloarthritis (SpA)
Number of subjects: 950
Study 21821621 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of clinical items indicative of inflammatory back pain
Number of subjects: 950
Study 19575689 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrageenan-based microbicide
Number of subjects: 165
Study 19575689 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study 17450102 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV) exposure during pregnancy
Number of subjects: 451
Study 17450102 — intervention group
Group type: COMPARATOR
Intervention: Non-EFV exposure during pregnancy
Number of subjects: 451
Study 14717627 — intervention group
Group type: EXPERIMENTAL
Intervention: Messages framed with emotional overtones matching the emotional state of the receiver (sadness)
Number of subjects: 2
Study 14717627 — intervention group
Group type: EXPERIMENTAL
Intervention: Messages framed with emotional overtones matching the emotional state of the receiver (anger)
Number of subjects: 2
Study 14717627 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion-induced expectancies attached to arguments in messages
Number of subjects: 2
Study 11289194 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin 400 mg
Number of subjects: 728
Study 11289194 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin 600 mg
Number of subjects: 728
Study 11289194 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin 400 mg
Number of subjects: 728
Study 11289194 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 728
Study 11289194 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin 400 mg and 600 mg, Ofloxacin 400 mg
Number of subjects: 728
Study 9263159 — intervention group
Group type: EXPERIMENTAL
Intervention: MOS Short Form 36 (SF‐36)
Number of subjects: 150
Study 8174010 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain MRI with normal neurological examination
Number of subjects: 16
Study 8174010 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain MRI with abnormal neurological examination
Number of subjects: 16
Study 8174010 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical neurological examination
Number of subjects: 16
Study 3606238 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous closed suction drainage
Number of subjects: 194
Study 3606238 — intervention group
Group type: COMPARATOR
Intervention: Simple abdominal closure
Number of subjects: 194
Study 3606238 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound infections
Number of subjects: 194
Study 3606238 — intervention group
Group type: COMPARATOR
Intervention: Wound infections (subgroup analysis)
Number of subjects: 194
Study 29044862 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine plus cisplatin chemotherapy
Number of subjects: 40
Study 27942103 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose treatment (5 mg/kg)
Number of subjects: 80
Study 27942103 — intervention group
Group type: COMPARATOR
Intervention: Multiple doses (1.7 mg/kg three times a day)
Number of subjects: 80
Study 25640401 — intervention group
Group type: EXPERIMENTAL
Intervention: 3h-AFL-PDT
Number of subjects: 93
Study 25640401 — intervention group
Group type: EXPERIMENTAL
Intervention: 2h-AFL-PDT
Number of subjects: 93
Study 25640401 — intervention group
Group type: COMPARATOR
Intervention: 3h-MAL-PDT
Number of subjects: 93
Study 23331997 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote sensing method using GIS, Google Earth, Microsoft Excel, and handheld Garmin GPSmap 76CSx GPS units
Number of subjects: 537
Study 20513659 — intervention group
Group type: EXPERIMENTAL
Intervention: High-scoring individuals on the Autism Spectrum Quotient
Number of subjects: 29
Study 20513659 — intervention group
Group type: COMPARATOR
Intervention: Low-scoring individuals on the Autism Spectrum Quotient
Number of subjects: 29
Study 18308165 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 3560
Study 18308165 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 3560
Study 16482084 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of 17‐beta estradiol
Number of subjects: 15
Study 16482084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 12904894 — intervention group
Group type: EXPERIMENTAL
Intervention: Eniluracil (20 mg orally twice daily)
Number of subjects: 23
Study 12904894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 12904894 — intervention group
Group type: EXPERIMENTAL
Intervention: Eniluracil (8 and 7 days prior to surgery)
Number of subjects: 23
Study 10828236 — intervention group
Group type: EXPERIMENTAL
Intervention: Duplex scan
Number of subjects: 103
Study 10828236 — intervention group
Group type: COMPARATOR
Intervention: CT scan
Number of subjects: 103
Study 9356001 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized surfactant (palmitoylphosphadidylcholine [DPPC]) 607.5 mg/d for 2 weeks
Number of subjects: 87
Study 9356001 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 87
Study 8472446 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic subacromial decompression (ASD)
Number of subjects: 20
Study 8472446 — intervention group
Group type: COMPARATOR
Intervention: Open acromioplasty according to Neer
Number of subjects: 20
Study 3485390 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine, 1 mg/kg intravenously 5 min before aortic unclamping and cardiac reperfusion, followed by infusion at 40 micrograms X kg‐1 X min‐1
Number of subjects: 20
Study 3485390 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 31924544 — intervention group
Group type: EXPERIMENTAL
Intervention: OPT-302 monotherapy (2 mg)
Number of subjects: 51
Study 31924544 — intervention group
Group type: EXPERIMENTAL
Intervention: OPT-302 (2 mg) combined with ranibizumab (0.5 mg)
Number of subjects: 51
Study 29633644 — intervention group
Group type: EXPERIMENTAL
Intervention: KT‐11 food tablet (1.2×10^10 KT‐11 cells)
Number of subjects: 16
Study 29633644 — intervention group
Group type: COMPARATOR
Intervention: Placebo food tablet (without KT‐11)
Number of subjects: 16
Study 28689898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28689898 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (10 mg/day to 60 mg/day)
Number of subjects: 0
Study 28689898 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (60 mg/day)
Number of subjects: 0
Study 28689898 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (35 mg/day)
Number of subjects: 0
Study 25138758 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% cord blood serum (CBS)
Number of subjects: 144
Study 25138758 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% autologous serum (ALS)
Number of subjects: 144
Study 25138758 — intervention group
Group type: COMPARATOR
Intervention: Preservative-free artificial tear (AT) drops
Number of subjects: 144
Study 23334732 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (70 mg weekly) plus exercise (using ARED)
Number of subjects: 7
Study 23334732 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise using ARED
Number of subjects: 7
Study 23334732 — intervention group
Group type: COMPARATOR
Intervention: Exercise using the interim resistance exercise device
Number of subjects: 7
Study 23334732 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of exercise plus antiresorptive drug (alendronate)
Number of subjects: 7
Study 22008228 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (MTCP) 20 mg IV
Number of subjects: 26
Study 22008228 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine (DPH) 50 mg IV
Number of subjects: 26
Study 22008228 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 26
Study 19037043 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid-based cytology
Number of subjects: 89784
Study 16612587 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal (123)I‐MIBG uptake in IVF patients
Number of subjects: 20
Study 16612587 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal (123)I‐MIBG uptake in IVF patients
Number of subjects: 20
Study 16612587 — intervention group
Group type: EXPERIMENTAL
Intervention: Sympathetic innervation impairment
Number of subjects: 20
Study 16612587 — intervention group
Group type: COMPARATOR
Intervention: Control group (medullary carcinoma patients)
Number of subjects: 20
Study 14525751 — intervention group
Group type: EXPERIMENTAL
Intervention: High-viscosity octylcyanoacrylate (OCA) tissue adhesive
Number of subjects: 84
Study 14525751 — intervention group
Group type: COMPARATOR
Intervention: Low-viscosity octylcyanoacrylate (OCA) tissue adhesive
Number of subjects: 84
Study 10824361 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 60
Study 10824361 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin and low-fat diet
Number of subjects: 60
Study 8866496 — intervention group
Group type: EXPERIMENTAL
Intervention: Idebenone (antioxidant and enhancer of oxidative metabolism)
Number of subjects: 100
Study 8866496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 1473740 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chlorambucil and cisplatin
Number of subjects: 369
Study 1473740 — intervention group
Group type: COMPARATOR
Intervention: Sequential chlorambucil followed by cisplatin on treatment failure
Number of subjects: 369
Study 1473740 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive cancer with residuum less than 2 cm after initial surgery
Number of subjects: 369
Study 1473740 — intervention group
Group type: COMPARATOR
Intervention: Invasive cancer with more tumor residuum
Number of subjects: 369
Study 1473740 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete clinical response
Number of subjects: 369
Study 1473740 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete surgical response
Number of subjects: 369
Study 1473740 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumors of low malignant potential
Number of subjects: 369
Study 6424041 — intervention group
Group type: COMPARATOR
Intervention: Phenobarbital (PH)
Number of subjects: 69
Study 6424041 — intervention group
Group type: COMPARATOR
Intervention: Sodium Valproate (SV)
Number of subjects: 69
Study 6424041 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PO)
Number of subjects: 69